Aquinox Pharmaceuticals Inc. CEO David Main called bladder pain syndrome/interstitial cystitis (BPS/IC) "a sizable opportunity that few appreciate," but Wall Street's reaction to phase II secondary endpoint data with AQX-1125 suggested investors were climbing aboard in hordes, as the firm (NASDAQ:AQXP) closed trading Friday at $10.42, up $8.63, or 482 percent.